Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
Warning: file_get_contents(http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=20630094&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 445
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 Rubinstein JC; Sznol M; Pavlick AC; Ariyan S; Cheng E; Bacchiocchi A; Kluger HM; Narayan D; Halaban RJ Transl Med 2010[Jul]; 8 (ä): 67Activating mutations in BRAF kinase are common in melanomas. Clinical trials with PLX4032, the mutant-BRAF inhibitor, show promising preliminary results in patients selected for the presence of V600E mutation. However, activating V600K mutation is the other most common mutation, yet patients with this variant are currently excluded from the PLX4032 trials. Here we present evidence that a patient bearing the BRAF V600K mutation responded remarkably to PLX4032, suggesting that clinical trials should include all patients with activating BRAF V600E/K mutations.|Amino Acid Substitution/genetics[MESH]|Base Sequence[MESH]|DNA Mutational Analysis[MESH]|Humans[MESH]|Indoles/*therapeutic use[MESH]|Melanoma/*drug therapy/enzymology/*genetics[MESH]|Molecular Sequence Data[MESH]|Mutation/*genetics[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH]|Proto-Oncogene Proteins B-raf/*genetics[MESH]|Skin Neoplasms/*drug therapy/enzymology/*genetics[MESH]|Sulfonamides/*therapeutic use[MESH]|Vemurafenib[MESH] |
